Time filter

Source Type

PubMed | From the Institute for the Application of Nuclear Energy INEP, University of Belgrade and Institute for Endocrinology
Type: | Journal: American journal of clinical pathology | Year: 2016

Papillary thyroid carcinoma (PTC) usually has a good prognosis, but some patients develop an aggressive course of the disease, leading to a poor outcome. Vascular endothelial growth factor C (VEGF-C) and matrix metalloproteinase 9 (MMP-9) have been shown to play roles in tumor progression in various human malignancies.We analyzed VEGF-C and active MMP-9 expression profiles in PTC samples using immunohistochemistry and Western blotting.Immunohistochemistry showed positive staining for VEGF-C and active MMP-9 in 83% and 57% of PTCs, respectively (n=60), with a positive correlation between their expression levels (Spearman, P <.001). Concomitant high expression of VEGF-C and active MMP-9 correlated with the presence of lymph node metastasis (P =.005), pT status (P =.004), pTNM tumor stage (P =.005), and particularly the degree of tumor infiltration (P <.001, Fisher exact test). Densitometric analysis of Western blot bands confirmed correlation between VEGF-C and active MMP-9 expression (Wilcoxon and Spearman tests) and significant association with the clinicopathologic parameters (Mann-Whitney and Kruskal-Wallis tests).Association of coexpressed high levels of VEGF-C and active MMP-9 with lymphatic spreading and local invasiveness of PTC suggests their potential usefulness as predictive biomarkers of aggressive PTC behavior.

Loading From the Institute for the Application of Nuclear Energy INEP collaborators
Loading From the Institute for the Application of Nuclear Energy INEP collaborators